Here's a classic biotech story: promising science meets the hard math of the balance sheet. Metagenomi, Inc. (MGX) shared new data Tuesday for its lead hemophilia A gene therapy candidate, MGX-001. The numbers from primate studies look good—good enough for the company to call the activity "curative." But to afford the long, expensive road to getting this therapy into humans, Metagenomi is making some painful cuts, laying off a quarter of its workforce.
The idea is to focus resources like a laser on its most advanced programs. That means MGX-001 for hemophilia A, related therapies for other protein disorders, and some cardiometabolic work it's doing with Ionis Pharmaceuticals Inc. (IONS). To pay for that focus, the company is scaling back on early-stage discovery and platform research. The result? A 25% smaller team, but a cash runway now expected to last into the fourth quarter of 2027.
So, what's the promising data that's justifying this all-in bet? It comes from a dose-finding study in 24 non-human primates. They were given a single dose of a viral vector (AAV) carrying a human gene for Factor VIII—the clotting protein that's missing or defective in people with hemophilia A.
The goal for a functional cure is generally to get a patient's Factor VIII activity into the range of 50% to 150% of normal levels. In this study, Metagenomi says the five highest AAV doses hit "therapeutically relevant" levels. Importantly, no animal went over the 150% ceiling, which is a safety concern. The treatment was mostly well-tolerated, with only the highest dose of a companion lipid nanoparticle (LNP) causing some temporary liver enzyme spikes.
For a proposed future human dose, the numbers looked like this: an average Factor VIII activity of 49%, with results for individual animals falling between 29.3% and 59.5%. That's knocking on the door of the target range, which is why the company is confident enough to plan its next regulatory moves.
Those moves are now the center of the company's universe. Metagenomi expects to have a key pre-IND (Investigational New Drug) meeting with regulators in the last quarter of 2025. If that goes well, the plan is to submit the formal IND and clinical trial applications in the fourth quarter of 2026.
It's a long runway, but it needs to be. The company reported having $184.1 million in cash, cash equivalents, and marketable securities at the end of the last quarter. The strategic shift and staff reduction are all about making that money last to hit those 2026 milestones without needing to raise more in a tough market.
Investors, however, seemed to be focusing on the cost of the pivot today. Metagenomi shares were down sharply, falling about 15.7% to $1.85 at the time of publication. It's the biotech balancing act in action: betting the future on a lead program often means sacrificing parts of the present.
